Fluidigm (NASDAQ:FLDM) is up 27% premarket in reaction to its filing
for Emergency Use Authorization (EUA) for an extraction-free
saliva-based test, Advanta Dx SARS-CoV-2 RT-PCR test, to detect the
SARS‑CoV‑2 virus.
The test, developed in collaboration with
McDonnell Genome Institute and Washington University School of
Medicine, provides an easy-to-administer protocol that does not require
collection via invasive nasopharyngeal swab and is processed on the
Biomark HD microfluidics platform.
https://seekingalpha.com/news/3582883-fluidigm-files-for-emergency-use-of-saliva-based-test-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.